Metabolic Research, Inc.
OTC Bulletin Board : MTBR

Metabolic Research, Inc.

March 27, 2007 12:57 ET

Metabolic Research, Inc. Forms Pharmaceutical Division

MONTGOMERY, TEXAS--(CCNMatthews - March 27, 2007) - Metabolic Research, Inc. (OTCBB:MTBR) announced today the Company's restructuring into two divisions. The Nutraceutical Division will continue the Company's mandate to acquire or develop and market "nutraceutical" products, and the Pharmaceutical Division will research and develop new pharmaceutical drugs.

"Metabolic Research's newly formed Pharmaceutical division will focus on promising drug candidates that will be developed within the guidelines of the FDA. Our research into natural medicines, especially the world of fungi properties of both processes and drugs developed in the new Division will complement the product lines of the Nutraceutical Division," says Nick Montesano, Chief Executive Officer of Metabolic Research, Inc.

The initial research of the new Division will center on the physiological, therapeutic, and immunological properties and effects of derivatives of the Agaricus blazei Murrill mushroom as it pertains to cancer and other debilitating maladies.

About Metabolic Research, Inc.

Metabolic Research, Inc. intends to develop a new form of pharmaceutical-grade non-synthetic pharmaceuticals to safely and effectively treat inflammatory diseases. Metabolic Research's proprietary process is based on "growing" drugs by using natural metabolic processes of plants or fungus rather than chemical synthesis used by traditional pharmaceutical companies. For more information, please visit the company's website at: www.metabolicresearchinc.com.

This press release may include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. The Company's actual results could differ materially from those anticipated in the forward-looking statements. The Company refers you to the cautionary statements and risk factors set forth in the documents it files with the Securities and Exchange Commission. Neither the Company nor Phoenix IR Associates is under any obligation (and expressly disclaims any obligation) to update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.

Forward Looking Statements

This press release may include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. The Company's actual results could differ materially from those anticipated in the forward-looking statements. The Company refers you to the cautionary statements and risk factors set forth in the documents it files with the Securities and Exchange Commission. Neither the Company nor Phoenix IR Associates is under any obligation (and expressly disclaims any obligation) to update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact Information